Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HB eAg seroconversion is associated with high relapse rates and fatal outcomes
Alimentary Pharmacology & Therapeutics2018Vol. 47(8), pp. 1170–1180
Citations Over TimeTop 10% of 2018 papers
Stijn Van Hees, Stefan Bourgeois, Hans Van Vlierberghe, Thomas Sersté, Sven Francque, P. Michielsen, D. Sprengers, Hendrik Reynaert, Jean Henrion, Sergio Negrin Dastis, Jean Delwaide, Luc Lasser, Jochen Decaestecker, Hans Orlent, Filip Janssens, Geert Robaeys, Isabelle Colle, Peter Stärkel, Christophe Moreno, Frederik Nevens, Thomas Vanwolleghem, Belgian NA Stop Study Group
Abstract
Treatment withdrawal in Caucasian chronic hepatitis B patients after nucleos(t)ide analogue-induced HBeAg seroconversion results in viral relapses in more than half of patients with potential fatal outcomes. These real-world data further lend support to preferentially continue NA treatment after HBeAg seroconversion until HBsAg loss.
Related Papers
- → Relationship between hepatitis B core‐related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues(2019)20 cited
- Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985-2002.(2005)
- → Comparison of Seroconversion Rates with Three Kinds of Recombinant Hepatitis B Vaccines(1999)2 cited
- → The natural history of HBV carriers. Seroconversion and seronegative of HBs.(1988)2 cited
- → High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behavior measures: Results from the DETECTCoV-19 cohort.(2021)2 cited